A novel human cytomegalovirus locus modulates cell type-specific outcomes of infection

PLoS Pathogens

Volumn 7, Issue 12, 2011, Pages

  Umashankar, Mahadevaiah ^a   Petrucelli, Alex ^b   Cicchini, Louis ^a   Caposio, Patrizia ^c   Kreklywich, Craig N ^c   Rak, Michael ^a   Bughio, Farah ^a   Goldman, Devorah C ^c   Hamlin, Kimberly L ^c   Nelson, Jay A ^c   Fleming, William H ^c   Streblow, Daniel N ^c   Goodrum, Felicia ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CD34 SELECTION; CELL TYPE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FIBROBLAST; GENE LOCUS; GENE SEQUENCE; GOLGI COMPLEX; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STEM CELL MOBILIZATION; VIRUS REPLICATION;

ANIMALS; CELL LINE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; GENETIC LOCI; HEMATOPOIETIC STEM CELLS; HOST-PATHOGEN INTERACTIONS; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; VIRAL TROPISM; VIRUS REPLICATION;

HUMAN HERPESVIRUS 5; MAMMALIA; PRIMATES;

EID: 84855264029     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002444     Document Type: Article

References (46)

1. Horvath R, Cerny J, Benedik J Jr, Hokl J, Jelinkova I, et al. (2000) The possible role of human cytomegalovirus (HCMV) in the origin of atherosclerosis. J Clin Virol 16: 17-24.
2. Streblow DN, Orloff SL, Nelson JA, (2001) Do pathogens accelerate atherosclerosis? J Nutr 131: 2798S-2804S.
3. Moss P, (2010) The emerging role of cytomegalovirus in driving immune senescence: a novel therapeutic opportunity for improving health in the elderly. Curr Opin Immunol 22: 529-534.
4. Brunner S, Herndler-Brandstetter D, Weinberger B, Grubeck-Loebenstein B, (2011) Persistent viral infections and immune aging. Ageing Res Rev 10: 362-369.
5. Pawelec G, Derhovanessian E, (2011) Role of CMV in immune senescence. Virus Res 157: 175-179.
6. High KP, (2005) Chronic infection and frailty: surrogate markers, associations, and causality. J Am Geriatr Soc 53: 906-908.
7. Schmaltz HN, Fried LP, Xue QL, Walston J, Leng SX, et al. (2005) Chronic cytomegalovirus infection and inflammation are associated with prevalent frailty in community-dwelling older women. J Am Geriatr Soc 53: 747-754.
8. Wang GC, Kao WH, Murakami P, Xue QL, Chiou RB, et al. (2010) Cytomegalovirus infection and the risk of mortality and frailty in older women: a prospective observational cohort study. Am J Epidemiol 171: 1144-1152.
9. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, et al. (2003) Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. Biol Blood Marrow Transplant 9: 543-558.
10. Huang L, Crothers K, (2009) HIV-associated opportunistic pneumonias. Respirology 14: 474-485.
11. Kedhar SR, Jabs DA, (2007) Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Herpes 14: 66-71.
12. Mocarski ES, Shenk T, Pass RF, (2007) Cytomegaloviruses. In: Knipe DM, Howley PM, editors. Fields Virology.5 ed Philadelphia Lippincott, Williams & Wilkins pp. 2701-2673.
13. Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R, (2004) Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis 39: 233-239.
14. Syggelou A, Iacovidou N, Kloudas S, Christoni Z, Papaevangelou V, (2010) Congenital cytomegalovirus infection. Ann N Y Acad Sci 1205: 144-147.
15. Cha TA, Tom E, Kemble GW, Duke GM, Mocarski ES, et al. (1996) Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J Virol 70: 78-83.
16. Dolan A, Cunningham C, Hector RD, Hassan-Walker AF, Lee L, et al. (2004) Genetic content of wild-type human cytomegalovirus. J Gen Virol 85: 1301-1312.
17. Murphy E, Yu D, Grimwood J, Schmutz J, Dickson M, et al. (2003) Coding potential of laboratory and clinical strains of human cytomegalovirus. Proc Natl Acad Sci USA 100: 14976-14981.
18. Goodrum F, Reeves M, Sinclair J, High K, Shenk T, (2007) Human cytomegalovirus sequences expressed in latently infected individuals promote a latent infection in vitro. Blood 110: 937-945.
19. Petrucelli A, Rak M, Grainger L, Goodrum F, (2009) Characterization of a Novel Golgi-localized Latency Determinant Encoded by Human Cytomegalovirus. J Virol 83: 5615-5629.
20. Le VT, Trilling M, Hengel H, (2011) The Cytomegaloviral Protein pUL138 Acts as Potentiator of TNF Receptor 1 Surface Density to Enhance ULb′-encoded modulation of TNF-{alpha} Signaling. J Virol 85: 13260-13270.
21. Montag C, Wagner JA, Gruska I, Vetter B, Wiebusch L, et al. (2011) The latency-associated UL138 gene product of human cytomegalovirus sensitizes cells to tumor necrosis factor alpha (TNF-alpha) signaling by upregulating TNF-alpha receptor 1 cell surface expression. J Virol 85: 11409-11421.
22. Grainger L, Cicchini L, Rak M, Petrucelli A, Fitzgerald KD, et al. (2010) Stress-Inducible Alternative Translation Initiation of Human Cytomegalovirus Latency Protein pUL138. J Virol 84: 9472-9486.
23. Pischel KD, Little JR, (1979) Limited trypsin cleavage distinguishes MHC and thymus-leukemia antigens. J Immunol 123: 551-556.
24. Stam NJ, Spits H, Ploegh HL, (1986) Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 137: 2299-2306.
25. Goodrum FD, Jordan CT, High K, Shenk T, (2002) Human cytomegalovirus gene expression during infection of primary hematopoietic progenitor cells: a model for latency. Proc Natl Acad Sci USA 99: 16255-16260.
26. Goodrum F, Jordan CT, Terhune SS, High KP, Shenk T, (2004) Differential outcomes of human cytomegalovirus infection in primitive hematopoietic subpopulations. Blood 104: 687-695.
27. Smith MS, Goldman DC, Bailey AS, Pfaffle DL, Kreklywich CN, et al. (2010) Granulocyte-colony stimulating factor reactivates human cytomegalovirus in a latently infected humanized mouse model. Cell Host Microbe 8: 284-291.
28. Datta RS, Meacham C, Samad B, Neyer C, Sjolander K, (2009) Berkeley PHOG: PhyloFacts orthology group prediction web server. Nucleic Acids Res 37: W84-89.
29. Kelley LA, Sternberg MJ, (2009) Protein structure prediction on the Web: a case study using the Phyre server. Nat Protoc 4: 363-371.
30. Tompa P, (2005) The interplay between structure and function in intrinsically unstructured proteins. FEBS Lett 579: 3346-3354.
31. Oxford KL, Eberhardt MK, Yang KW, Strelow L, Kelly S, et al. (2008) Protein coding content of the UL)b′ region of wild-type rhesus cytomegalovirus. Virology 373: 181-188.
32. Tomasec P, Wang EC, Davison AJ, Vojtesek B, Armstrong M, et al. (2005) Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141. Nat Immunol 6: 181-188.
33. Wills MR, Ashiru O, Reeves MB, Okecha G, Trowsdale J, et al. (2005) Human cytomegalovirus encodes an MHC class I-like molecule (UL142) that functions to inhibit NK cell lysis. J Immunol 175: 7457-7465.
34. Benedict CA, Butrovich KD, Lurain NS, Corbeil J, Rooney I, et al. (1999) Cutting edge: a novel viral TNF receptor superfamily member in virulent strains of human cytomegalovirus. J Immunol 162: 6967-6970.
35. Poole E, King CA, Sinclair JH, Alcami A, (2006) The UL144 gene product of human cytomegalovirus activates NFkappaB via a TRAF6-dependent mechanism. Embo J 25: 4390-4399.
36. Penfold ME, Dairaghi DJ, Duke GM, Saederup N, Mocarski ES, et al. (1999) Cytomegalovirus encodes a potent alpha chemokine. Proc Natl Acad Sci USA 96: 9839-9844.
37. Brune W, Nevels M, Shenk T, (2003) Murine cytomegalovirus m41 open reading frame encodes a Golgi-localized antiapoptotic protein. J Virol 77: 11633-11643.
38. Hicks SW, Machamer CE, (2005) Golgi structure in stress sensing and apoptosis. Biochim Biophys Acta 1744: 406-414.
39. Miller CL, Eaves CJ, (2002) Long-term culture-initiating cell assays for human and murine cells. In: Klug CA, Jordan CT, editors. Hematopoietic Stem Cell Protocols Totowa Humana Press pp. 123-141.
40. Warming S, Costantino N, Court DL, Jenkins NA, Copeland NG, (2005) Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res 33: e36.
41. Yu D, Ellis HM, Lee EC, Jenkins NA, Copeland NG, et al. (2000) An efficient recombination system for chromosome engineering in Escherichia coli. Proc Natl Acad Sci USA 97: 5978-5983.
42. Hahn G, Khan H, Baldanti F, Koszinowski UH, Revello MG, et al. (2002) The human cytomegalovirus ribonucleotide reductase homolog UL45 is dispensable for growth in endothelial cells, as determined by a BAC-cloned clinical isolate of human cytomegalovirus with preserved wild-type characteristics. J Virol 76: 9551-9555.
43. Revello MG, Lilleri D, Zavattoni M, Stronati M, Bollani L, et al. (2001) Human cytomegalovirus immediate-early messenger RNA in blood of pregnant women with primary infection and of congenitally infected newborns. J Infect Dis 184: 1078-1081.
44. Sinzger C, Hahn G, Digel M, Katona R, Sampaio KL, et al. (2008) Cloning and sequencing of a highly productive, endotheliotropic virus strain derived from human cytomegalovirus TB40/E. J Gen Virol 89: 359-368.
45. Pfaffl MW, (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
46. Hu Y, Smyth GK, (2009) ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 347: 70-78.